Although the average risk of acquiring HIV infection after percutaneous exposure to HIV-
infected blood is only 0.3%,(f. 1) health care workers welcomed the news that postexposure …

CURRENT PRACTICE: The use of anti-retrovirals in post-exposure prophylaxis has
progressed tremendously in France since 1988. The ministerial recommendations of April …

Abstract In 1996, the Centers for Disease Control and Prevention (CDC) published a case-
control study demonstrating that post-exposure treatment with zidovudine was associated …

Since 1990, 11 cases of failure of zidovudine (ZDV) postexposure prophylaxis (PEP) for
human immunodeficiency virus (HIV) exposure have been reported among healthcare …

Background The average risk of human immunodeficiency virus (HIV) infection after
percutaneous exposure to HIV-infected blood is 0.3 percent, but the factors that influence …

Healthcare workers are at risk of occupationally acquired HIV infection primarily due to
percutaneous exposure to HIV infected blood. The average risk of HIV transmission after …

Sound scientific information with which to determine the true efficacy of zidovudine for
prophylaxis will probably not be available soon. Physicians should educate themselves …

P revious speakers at this workshop have ad-dressed issues relating to the toxicity of
antiretroviral agents, particularly zidovudine. Much of this material does not need to be …

The CDC recently published updated recommendations for chemoprophylaxis after
occupational exposure to human immunodeficiency virus (HIV). The recommendations were …

Treatment with zidovudine after occupational exposure to HIV decreased the chance of HIV
infection by 79% in a case–control study [1]. The study led to recommendations that …